An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works

Drug penetration in solid tumours

Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · see citing works

Intra-tumour heterogeneity: a looking glass for cancer?

Marusyk, A., Almendro, V., & Polyák, K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3261 · Cited by 2,003 · see citing works

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · see citing works

Small-scale systems for in vivo drug delivery

LaVan, D. A., McGuire, T., & Langer, R. (2003) · Nature Biotechnology · doi:10.1038/nbt876 · Cited by 1,301 · see citing works

Sequence analysis of mutations and translocations across breast cancer subtypes

Banerji, S. O., Cibulskis, K., Rangel‐Escareño, C., Brown, K., Carter, S. L., Frederick, A. M., Lawrence, M. S., Sivachenko, A., Sougnez, C. L., Zou, L., et al. (2012) · Nature · doi:10.1038/nature11154 · Cited by 1,181 · see citing works

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · see citing works

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · see citing works

The productivity crisis in pharmaceutical R&D

Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918 · see citing works

Overview of resistance to systemic therapy in patients with breast cancer

Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904 · see citing works

Triple-Negative Breast Cancer: An Unmet Medical Need

Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 783 · see citing works

Triple-negative breast cancer: disease entity or title of convenience?

Carey, L., Winer, E. P., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 780 · see citing works

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761 · see citing works

Colon Cancer

Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y., Choti, M. A., Cooper, H. S., Covey, A. M., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0056 · Cited by 682 · see citing works

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 681 · see citing works

Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Sundaram, S. K., Sam, L. T., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 629 · see citing works

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 582 · see citing works

A BioMEMS Review: MEMS Technology for Physiologically Integrated Devices

Grayson, A. C. R., Shawgo, R. S., Johnson, A. M., Flynn, N. T., Li, Y., Cima, M. J., & Langer, R. (2004) · Proceedings of the IEEE · doi:10.1109/jproc.2003.820534 · Cited by 563 · see citing works

Body condition scoring: a rapid and accurate method for assessing health status in mice.

Ullman-Culleré, M., & Foltz, C. J. (1999) · PubMed · Cited by 545 · see citing works

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M. R., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 477 · see citing works

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip

Farra, R., Sheppard, N. F., McCabe, L., Neer, R. M., Anderson, J., Santini, J. T., Cima, M. J., & Langer, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003276 · Cited by 442 · see citing works

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386 · see citing works

Personalized medicine in oncology: the future is now

Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 340 · see citing works

Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?

Overman, M. J., Modak, J. M., Kopetz, S., Murthy, R., Yao, J. C., Hicks, M. E., Abbruzzese, J. L., & Tam, A. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1718 · Cited by 315 · see citing works

Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

Holbeck, S. L., Collins, J. M., & Doroshow, J. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0106 · Cited by 312 · see citing works

Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.

Fung, L. K., Ewend, M. G., Sills, A. K., Sipos, E. P., Thompson, R. C., Watts, M., Colvin, O. M., Brem, H., & Saltzman, W. M. (1998) · PubMed · Cited by 289 · see citing works

Spending on new drug development1

Adams, C., & Brantner, V. V. (2009) · Health Economics · doi:10.1002/hec.1454 · Cited by 277 · see citing works

Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity

Almendro, V., Cheng, Y.-K., Randles, A. P., Itzkovitz, S., Marusyk, A., Ametller, E., González, X., Muñoz-Mateu, M., Russnes, H. G., Helland, Å., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.041 · Cited by 275 · see citing works

Adaptive clinical trials in oncology

Berry, D. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.165 · Cited by 268 · see citing works

Compressing drug development timelines in oncology using phase '0' trials

Kummar, S., Kinders, R. J., Rubinstein, L., Parchment, R. E., Murgo, A. J., Collins, J. M., Pickeral, O. K., Low, J. A., Steinberg, S. M., Gutierrez, M. E., et al. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2066 · Cited by 214 · see citing works

High-Throughput Methods for Combinatorial Drug Discovery

Sun, X., Vilar, S., & Tatonetti, N. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006667 · Cited by 200 · see citing works

Genetic and Phenotypic Diversity in Breast Tumor Metastases

Almendro, V., Kim, H. J., Cheng, Y.-K., Gönen, M., Itzkovitz, S., Argani, P., van Oudenaarden, A., Sukumar, S. V., Franziska Michor, A., & Polyák, K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2357-t · Cited by 174 · see citing works

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Tao, J. J., Castel, P., Radosevic‐Robin, N., Elkabets, M., Auricchio, N., Aceto, N., Weitsman, G. E., Barber, P. R., Vojnovic, B., Ellis, H., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005125 · Cited by 167 · see citing works

Management of breast cancer with targeted agents: importance of heterogenicity

Cosimo, S. D., & Baselga, J. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 159 · see citing works

The future of drug development: advancing clinical trial design

Orloff, J. J., Douglas, F. L., Pinheiro, J. C., Levinson, S. L., Branson, M., Chaturvedi, P. R., Ette, E., Gallo, P. P., Hirsch, G., Mehta, C. R., et al. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3025 · Cited by 158 · see citing works

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Ross, J. S., Wang, K., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Otto, G. A., He, J., Palmer, G. A., Yelensky, R., Lipson, D., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.135 · Cited by 147 · see citing works

Overcoming implementation challenges of personalized cancer therapy

Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 147 · see citing works

Drug development and clinical trials—the path to an approved cancer drug

Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135 · see citing works

Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments

Merz, F., Gaunitz, F., Dehghani, F., Renner, C., Meixensberger, J., Gutenberg, A., Giese, A., Schopow, K., Hellwig, C. T., Schäfer, M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not003 · Cited by 124 · see citing works

Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts

Baker, J. H. E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J., & Minchinton, A. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4465 · Cited by 124 · see citing works

Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy

Habermehl, D., Henkner, K., Ecker, S., Jäkel, O., Debus, J., & Combs, S. E. (2013) · Journal of Radiation Research · doi:10.1093/jrr/rrt071 · Cited by 94 · see citing works

Guidelines for Assessing the Health and Condition of Mice

Foltz, C. J., & Ullman-Culleré, M. (1999) · Laboratory animal science · Cited by 87 · see citing works

Correction: Reversal of Multidrug Resistance by Lapatinib

(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-24-cor · Cited by 86 · see citing works

Commentary

Garner, R. C., & Lappin, G. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02575.x · Cited by 79 · see citing works

Microregional Effects of Gemcitabine in HCT-116 Xenografts

Huxham, L. A., Kyle, A. H., Baker, J. H. E., Nykilchuk, L. K., & Minchinton, A. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0986 · Cited by 79 · see citing works

Spending on New Drug DevelopmentPreprint

Adams, C., & Brantner, V. V. (2005) · SSRN Electronic Journal · doi:10.2139/ssrn.869765 · Cited by 66 · see citing works

Time-and concentration-dependent penetration of doxorubicin in prostate tumors

Zheng, J., Chen, C., Au, J. L. ‐., & Wientjes, M. G. (2001) · AAPS PharmSci · doi:10.1208/ps030215 · Cited by 63 · see citing works

Image-Guided Radiotherapy

Sterzing, F., Engenhart‐Cabillic, R., Flentje, M. P., & Debus, J. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0274 · Cited by 61 · see citing works

Impact of Genomics on Personalized Cancer Medicine

Arteaga, C. L., & Baselga, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2019 · Cited by 57 · see citing works

Multi‐Reservoir Bioadhesive Microdevices for Independent Rate‐Controlled Delivery of Multiple Drugs

Chirra, H. D., & Desai, T. A. (2012) · Small · doi:10.1002/smll.201201367 · Cited by 54 · see citing works

Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): In vitro evaluation of efficacy and toxicity

Chang, L.-C., Liang, J. F., Lee, H.-F., Lee, L. M., & Yang, V. C.-M. (2001) · AAPS PharmSci · doi:10.1208/ps030318 · Cited by 52 · see citing works

Food and drug administration′s critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies

Mahajan, R., & Gupta, K. (2010) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.72130 · Cited by 49 · see citing works

Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression

Denisov, E. V., Литвяков, Н. В., Zavyalova, M. V., Михайлович, П. В., Vtorushin, S. V., Tsyganov, M. M., Gerashchenko, T. S., Garbukov, Е. Y., Slonimskaya, E. M., & Чердынцева, Н. В. (2014) · Scientific Reports · doi:10.1038/srep04709 · Cited by 43 · see citing works

Redefining Clinical Trials: The Age of Personalized Medicine

Vaidyanathan, G. (2012) · Cell · doi:10.1016/j.cell.2012.02.041 · Cited by 38 · see citing works

Novel Phenotypic Fluorescent Three-Dimensional Platforms for High-throughput Drug Screening and Personalized Chemotherapy

Fang, C., Avis, I. M., Salomon, D. S., & Cuttitta, F. F. (2013) · Journal of Cancer · doi:10.7150/jca.6780 · Cited by 18 · see citing works

In Vitro Antibiotic Testing and Its Relationship to Clinical Activity

Mouton, Y., & Dubreuil, L. (1997) · Journal of Chemotherapy · doi:10.1080/1120009x.1997.12113194 · Cited by 3 · see citing works

A view on drug resistance in cancer

Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770 · see citing works

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817 · see citing works

Emerging Frontiers in Drug Delivery

Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 982 · see citing works

Personalized medicine: motivation, challenges, and progress

Goetz, L. H., & Schork, N. J. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.006 · Cited by 976 · see citing works

A new chapter in pharmaceutical manufacturing: 3D-printed drug products

Norman, J. J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.001 · Cited by 832 · see citing works

Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy

Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642 · see citing works

Precision medicine for cancer with next-generation functional diagnostics

Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570 · see citing works

Enabling Technologies for Personalized and Precision Medicine

Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517 · see citing works

Functional precision cancer medicine—moving beyond pure genomics

Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366 · see citing works

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors

Davidson, S. M., Jonas, O., Keibler, M. A., Hou, H. W., Luengo, A., Mayers, J. R., Wyckoff, J., Del Rosario, A. M., Whitman, M., Chin, C. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4256 · Cited by 331 · see citing works

Independent Drug Action in Combination Therapy: Implications for Precision Oncology

Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 322 · see citing works

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations

Letai, A. G., Bhola, P. D., & Welm, A. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 282 · see citing works

Engineering and physical sciences in oncology: challenges and opportunities

Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273 · see citing works

Biopolymers for Antitumor Implantable Drug Delivery Systems: Recent Advances and Future Outlook

Talebian, S., Foroughi, J., Wade, S. J., Vine, K. L., Dolatshahi‐Pirouz, A., Mehrali, M., Conde, J., & Wallace, G. G. (2018) · Advanced Materials · doi:10.1002/adma.201706665 · Cited by 219 · see citing works

Engineering precision biomaterials for personalized medicine

Aguado, B. A., Grim, J. C., Rosales, A. M., Watson-Capps, J. J., & Anseth, K. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8645 · Cited by 216 · see citing works

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 211 · see citing works

Tumor Cell–Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression

Oudin, M. J., Jonas, O. H., Kosciuk, T., Broye, L. C., Guido, B. C., Wyckoff, J., Riquelme, D. N., Lamar, J. M., Asokan, S. B., Whittaker, C. A., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1183 · Cited by 206 · see citing works

Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and MetastasisPreprint

Oudin, M. J., & Weaver, V. M. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030817 · Cited by 198 · see citing works

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy

Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.028 · Cited by 194 · see citing works

The impact of tumour pH on cancer progression: strategies for clinical intervention

Ward, C., Meehan, J., Gray, M., Murray, A. F., Argyle, D. J., Kunkler, I. H., & Langdon, S. P. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00005 · Cited by 180 · see citing works

Implantable biosensors and their contribution to the future of precision medicine

Gray, M., Meehan, J., Ward, C., Langdon, S. P., Kunkler, I. H., Murray, A., & Argyle, D. J. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2018.07.011 · Cited by 170 · see citing works

Design and fabrication of drug‐delivery systems toward adjustable release profiles for personalized treatment

Geraili, A., Xing, M. M. Q., & Mequanint, K. (2021) · Open Research (University of Surrey) · doi:10.1002/viw.20200126 · Cited by 151 · see citing works

Molecular Diagnostics in Clinical Oncology

Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 144 · see citing works

Solid implantable devices for sustained drug delivery

Magill, E., Demartis, S., Gavini, E., Permana, A. D., Thakur, R. R. S., Adrianto, M. F., Waite, D. T., Glover, K., Picco, C. J., Korelidou, A., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114950 · Cited by 146 · see citing works

Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer

Hu, C. T., Liu, X., Ran, W., Meng, J., Zhai, Y., Zhang, P., Yin, Q., Yu, H., Zhang, Z., & Li, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.009 · Cited by 142 · see citing works

A flexible electronic strain sensor for the real-time monitoring of tumor regression

Abramson, A., Chan, C. T., Khan, Y., Mermin-Bunnell, A. M., Matsuhisa, N., Fong, R., Shad, R., Hiesinger, W., Mallick, P., Gambhir, S. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn6550 · Cited by 124 · see citing works

Microneedle-based delivery devices for cancer therapy: A review

Moreira, A. F., Rodrigues, C. F., Jacinto, T. A., Miguel, S. P., Costa, E. C., & Correia, I. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104438 · Cited by 123 · see citing works

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Stevens, M. M., Maire, C. L., Chou, N., Murakami, M. A., Knoff, D. S., Kikuchi, Y., Kimmerling, R. J., Liu, H., Haidar, S., Calistri, N. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3697 · Cited by 106 · see citing works

Drug screening of cancer cell lines and human primary tumors using droplet microfluidics

Wong, A. H., Li, H., Jia, Y., Mak, P., Martins, R. P., Liu, Y., Vong, C., Wong, H. C., Wong, P. K., Wang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08831-z · Cited by 105 · see citing works

Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy

Pan, S., Zhang, Y., Natalia, A., Lim, C. Z. J., Ho, N. R. Y., Chowbay, B., Loh, T. P., Tam, J. K. C., & Shao, H. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00872-w · Cited by 103 · see citing works

Biosensor-Integrated Drug Delivery Systems as New Materials for Biomedical Applications

Cicha, I., Priefer, R., Severino, P. B., Souto, E. B., & Jain, S. A. (2022) · Biomolecules · doi:10.3390/biom12091198 · Cited by 102 · see citing works

Phase 0/microdosing approaches: time for mainstream application in drug development?

Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 104 · see citing works

Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems

van Elk, M., Murphy, B. P., Eufrásio-da-Silva, T., O’Reilly, D. P., Vermonden, T., Hennink, W. E., Duffy, G. P., & Ruiz‐Hernández, E. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.013 · Cited by 97 · see citing works

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes

Watson, S. S., Dane, M. A., Chin, K., Tatárová, Z., Liu, M., Liby, T. A., Thompson, W., Smith, R. L., Nederlof, M. A., Bucher, E., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.02.001 · Cited by 91 · see citing works

Recent Advances in Micro-Electro-Mechanical Devices for Controlled Drug Release Applications

Villarruel, L. A., Scilletta, N. A., Bellino, M. G., Desimone, M. F., & Catalano, P. N. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00827 · Cited by 89 · see citing works

Multiplexed drug testing of tumor slices using a microfluidic platform

Horowitz, L. F., Rodriguez, A. D., Dereli-Korkut, Z., Lin, R., Castro, K., Mikheev, A. M., Monnat, R. J., Folch, A., & Rostomily, R. C. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0117-y · Cited by 88 · see citing works

Emerging Technologies for Local Cancer Treatment

Chua, C. Y. X., Ho, J., Demaria, S., Mauro Ferrari, B., & Grattoni, A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000027 · Cited by 85 · see citing works

Bioinspired Hydrogels to Engineer Cancer Microenvironments

Park, K. M., Lewis, D. M., & Gerecht, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044619 · Cited by 83 · see citing works

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions

Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 80 · see citing works

Patient-derived xenografts (PDXs) as model systems for human cancer

Invrea, F., Rovito, R., Torchiaro, E., Petti, C., Isella, C., & Médico, E. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.003 · Cited by 79 · see citing works

A microfluidic platform for functional testing of cancer drugs on intact tumor slices

Rodriguez, A. D., Horowitz, L. F., Castro, K., Kenerson, H., Bhattacharjee, N., Gandhe, G., Raman, A., Monnat, R. J., Yeung, R., Rostomily, R. C., et al. (2020) · Lab on a Chip · doi:10.1039/c9lc00811j · Cited by 77 · see citing works

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis

Arai, S., Jonas, O. H., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 71 · see citing works

Toward point-of-care assessment of patient response: a portable tool for rapidly assessing cancer drug efficacy using multifrequency impedance cytometry and supervised machine learning

Ahuja, K., Rather, G. M., Lin, Z., Sui, J., Xie, P., Le, T. D., Bertino, J. R., & Javanmard, M. (2019) · Microsystems & Nanoengineering · doi:10.1038/s41378-019-0073-2 · Cited by 73 · see citing works

Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy

Alimardani, V., Abolmaali, S. S., Tamaddon, A. M., & Ashfaq, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00819-z · Cited by 70 · see citing works

An in vivo multiplexed small-molecule screening platform

Grüner, B. M., Schulze, C. J., Yang, D., Ogasawara, D., Dix, M. M., Rogers, Z. N., Chuang, C.-H., McFarland, C. D., Chiou, S.-H., Brown, J. M., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3992 · Cited by 62 · see citing works

Microdissected “cuboids” for microfluidic drug testing of intact tissues

Horowitz, L. F., Rodriguez, A. D., Au-Yeung, A., Bishop, K. W., Barner, L. A., Mishra, G., Raman, A., Delgado, P., Liu, J. T. C., Gujral, T. S., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc00801j · Cited by 62 · see citing works

Novel drug delivery systems: Insight into self-powered and nano-enabled drug delivery systems

Ewii, U. E., Onugwu, A. L., Nwokpor, V. C., Akpaso, I.-A., Ogbulie, T. E., Aharanwa, B., Chijioke, C., Verla, N., Iheme, C. I., Ujowundu, C. O., et al. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100042 · Cited by 61 · see citing works

You Put What, Where?

Heffernan, K. J., Vetere, F., & Chang, S. (2016) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/2858036.2858392 · Cited by 58 · see citing works

Microfluidic technologies for wearable and implantable biomedical devices

Wang, Z., Shah, A., Lee, H., & Lee, C. H. (2025) · Lab on a Chip · doi:10.1039/d5lc00499c · Cited by 61 · see citing works

Communication protocols integrating wearables, ingestibles, and implantables for closed-loop therapies

Ghanim, R. W., Kaushik, A., Park, J., & Abramson, A. (2023) · Device · doi:10.1016/j.device.2023.100092 · Cited by 56 · see citing works

Integrated genetic and pharmacologic interrogation of rare cancers

Hong, A. L., Tseng, Y., Cowley, G. S., Jonas, O. H., Cheah, J. H., Kynnap, B. D., Doshi, M. B., Oh, C., Meyer, S. C., Church, A. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11987 · Cited by 54 · see citing works

REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks

Chatterjee, N., Whitman, M. A., Harris, C. A., Min, S. M., Jonas, O. H., Lien, E. C., Luengo, A., Heiden, M. G. V., Hong, J., Zhou, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016064117 · Cited by 55 · see citing works

Preclinical Models and Technologies in Glioblastoma Research: Evolution, Current State, and Future Avenues

Slika, H., Karimov, Z., Alimonti, P., Abou‐Mrad, T., Fazio, E. D., Alomari, S., & Tyler, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216316 · Cited by 49 · see citing works

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs

Tatárová, Z., Blumberg, D. C., Korkola, J. E., Heiser, L. M., Muschler, J. L., Schedin, P. S., Ahn, S. W., Mills, G. B., Coussens, L. M., Jonas, O. H., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01379-y · Cited by 50 · see citing works

Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers

Price, C. O., Gill, S., Ho, Z. V., Davidson, S. M., Merkel, E., McFarland, J. M., Leung, L., Tang, A., Kost‐Alimova, M., Tsherniak, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2674 · Cited by 46 · see citing works

Tissue-Agnostic Drug Development

Flaherty, K. T., Le, D. T., & Lemery, S. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_173855 · Cited by 46 · see citing works

First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development

Jonas, O. H., Calligaris, D., Methuku, K. R., Poe, M. M., Francois, J. P., Tranghese, F., Changelian, A. N., Sieghart, W., Ernst, M. C., Krummel, D. P., et al. (2016) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2016.2262 · Cited by 45 · see citing works

The Potential of Cryptophyte Algae in Biomedical and Pharmaceutical Applications

Abidizadegan, M., Peltomaa, E., & Blomster, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618836 · Cited by 46 · see citing works

Chemical Monitoring in Clinical Settings: Recent Developments toward Real-Time Chemical Monitoring of Patients

Booth, M. A., Gowers, S. A. N., Leong, C. L., Rogers, M. L., Samper, I. C., Wickham, A. P., & Boutelle, M. G. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04224 · Cited by 43 · see citing works

Microfluidics in Malignant Glioma Research and Precision Medicine

Logun, M. T., Zhao, W., Mao, L., & Karumbaiah, L. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700221 · Cited by 43 · see citing works

Microfluidics for interrogating live intact tissues

Horowitz, L. F., Rodriguez, A. D., Ray, T. R., & Folch, A. (2020) · Microsystems & Nanoengineering · doi:10.1038/s41378-020-0164-0 · Cited by 43 · see citing works

The past, present, and future of chemotherapy with a focus on individualization of drug dosing

DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 42 · see citing works

An Implantable Micro-Caged Device for Direct Local Delivery of Agents

Son, A. I., Opfermann, J. D., McCue, C., Ziobro, J. M., Abrahams, J. H., Jones, K., Morton, P. D., Ishii, S., Oluigbo, C. O., Krieger, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17912-y · Cited by 42 · see citing works

Covalent organic frameworks (COFs) as carrier for improved drug delivery and biosensing applications

Younas, R., Jubeen, F., Bano, N., Andreescu, S., Hong-xia, Z., & Hayat, A. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28718 · Cited by 39 · see citing works

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?

Sant, G. R., Knopf, K., & Albala, D. M. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0025-y · Cited by 37 · see citing works

Drug delivery across length scales

Delcassian, D., Patel, A. K., Cortinas, A. B., & Langer, R. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1438440 · Cited by 37 · see citing works

Advanced Devices for Tumor Diagnosis and Therapy

Wang, L., Dai, C., Jiang, L., Tong, G., Xiong, Y., Khan, K., Tang, Z., Chen, X., & Zeng, H. (2021) · Small · doi:10.1002/smll.202100003 · Cited by 36 · see citing works

Made-on-demand, complex and personalized 3D-printed drug products

Osouli-Bostanabad, K., & Adibkia, K. (2018) · Bioimpacts · doi:10.15171/bi.2018.09 · Cited by 35 · see citing works

Therapeutic potential of microbial modulation in pancreatic cancer

Chandra, V., & McAllister, F. M. (2021) · Gut · doi:10.1136/gutjnl-2019-319807 · Cited by 33 · see citing works

Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro‐in vivo correlation

Vogus, D. R., Pusuluri, A., Chen, R., & Mitragotri, S. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10082 · Cited by 32 · see citing works

VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells

Patterson, J. C., Joughin, B. A., Prota, A. E., Mühlethaler, T., Jonas, O. H., Whitman, M. A., Varmeh, S., Chen, S., Balk, S. P., Steinmetz, M. O., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.009 · Cited by 29 · see citing works

Flexible Transient Bioelectronic System Enables Multifunctional Active‐Controlled Drug Delivery

Liu, S., Jia, Z., Yang, F., Ning, T., Gu, X., Niu, X., & Fan, Y. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202215034 · Cited by 28 · see citing works

Synergistic interactions with PI3K inhibition that induce apoptosis

Zwang, Y., Jonas, O. H., Chen, C., Rinne, M. L., Doench, J. G., Piccioni, F., Tan, L., Huang, H., Wang, J., Ham, Y. J., et al. (2017) · eLife · doi:10.7554/elife.24523 · Cited by 28 · see citing works

Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform

Nguyen, T. N. H., Horowitz, L. F., Krilov, T., Lockhart, E. J., Kenerson, H. L., Gujral, T. S., Yeung, R. S. W., Arroyo‐Currás, N., & Folch, A. (2024) · Science Advances · doi:10.1126/sciadv.adn5875 · Cited by 27 · see citing works

Engineered miniaturized models of musculoskeletal diseases

Bersini, S., Arrigoni, C., Lopa, S., Bongio, M., Martín, I., & Moretti, M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.015 · Cited by 27 · see citing works

Biocompatibility of common implantable sensor materials in a tumor xenograft model

Gray, M., Meehan, J., Blair, E. O., Ward, C., Langdon, S. P., Morrison, L. R., Marland, J. R. K., Tsiamis, A., Kunkler, I. H., Murray, A., et al. (2018) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34254 · Cited by 25 · see citing works

Implantable Biomaterials for Cancer Immunotherapies

Печникова, Н. А., Aggeli, A., Latypova, A., Iaremenko, A. V., Domvri, K., Zubarev, I. V., Chuang, L. I. U., & Yaremenko, A. V. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202416813 · Cited by 25 · see citing works

Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas

Peruzzi, P., Dominas, C. A., Fell, G. G., Bernstock, J. D., Blitz, S. E., Mazzetti, D., Zdioruk, M. I., Dawood, H. Y., Triggs, D., Ahn, S. W., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0069 · Cited by 24 · see citing works

Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

Patterson, J. C., Varkaris, A. S., Croucher, P. J. P., Ridinger, M., Dalrymple, S. L., Nouri, M., Xie, F., Varmeh, S., Jonas, O. H., Whitman, M. A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1533 · Cited by 24 · see citing works

Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models

Flobak, Å., Skånland, S. S., Hovig, E. J., Taskén, K., & Russnes, H. G. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.08.009 · Cited by 21 · see citing works

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities

Jonas, O. H., Oudin, M. J., Kosciuk, T., Whitman, M. A., Gertler, F. B., Cima, M. J., Flaherty, K. T., & Langer, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2722 · Cited by 21 · see citing works

Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer

Gazdar, A. F., & Minna, J. D. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw119 · Cited by 21 · see citing works

Engineering Heterogeneous Tumor Models for Biomedical Applications

Wu, Z., Huang, D., Wang, J., Zhao, Y., Sun, W., & Shen, X. (2023) · Advanced Science · doi:10.1002/advs.202304160 · Cited by 19 · see citing works

Taxol reduces synergistic, mechanobiological invasiveness of metastatic cells

Merkher, Y., Alvarez‐Elizondo, M. B., & Weihs, D. (2017) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/aa8c0b · Cited by 18 · see citing works

Drug testing in the patient: Toward personalized cancer treatment

Coombes, R. C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1214 · Cited by 17 · see citing works

The prospects of tumor chemosensitivity testing at the single-cell level

Yang, C., Yang, C., Yarden, Y., To, K. K. W., & Fu, L. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100741 · Cited by 16 · see citing works

Bio-Internet of Things Through Micro-Circulation Network: A Molecular Communication Channel Modeling

Yue, G., Liu, Q., & Yang, K. (2024) · IEEE Internet of Things Journal · doi:10.1109/jiot.2024.3411048 · Cited by 17 · see citing works

In vivo detection of drug-induced apoptosis in tumors using Raman spectroscopy

Jonas, O. H., Kang, J. W., Singh, S. P., Lammers, A., Nguyen, F. T., Dasari, R. R., So, P. T. C., Langer, R., & Cima, M. J. (2018) · The Analyst · doi:10.1039/c8an00913a · Cited by 17 · see citing works

Understanding and embracing the complexities of the molecular communication channel in liquids

Wang, J., Hu, D., Shetty, C., & Hassanieh, H. (2020) · ACM Annual International Conference on Mobile Computing and Networking (MobiCom) · doi:10.1145/3372224.3419191 · Cited by 17 · see citing works

A Miniaturized Imaging Window to Quantify Intravital Tissue Regeneration within a 3D Microscaffold in Longitudinal Studies

Conci, C., Jacchetti, E., Sironi, L., Gentili, L., Cerullo, G., Osellame, R., Chirico, G. G., & Raimondi, M. T. (2022) · Advanced Optical Materials · doi:10.1002/adom.202101103 · Cited by 17 · see citing works

Overview of DNA repair pathways, current targets, and clinical trials bench to clinic

Kelley, M. R., & Fishel, M. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00001-2 · Cited by 17 · see citing works

Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma

Gundle, K. R., Deutsch, G. B., Goodman, H. J., Pollack, S. M., Thompson, M. J., Davis, J. L., Lee, M.-Y., Ramirez, D. C., Kerwin, W. S., Bertout, J. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0614 · Cited by 17 · see citing works

Strategies for Testing Intervention Matching Schemes in Cancer

Schork, N. J., Goetz, L. H., Lowey, J., & Trent, J. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1947 · Cited by 16 · see citing works

Strategic, feasibility, economic, and cultural aspects of phase 0 approaches

Burt, T., Roffel, A. F., Langer, O., Anderson, K., & DiMasi, J. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13269 · Cited by 15 · see citing works

Technological and computational advances driving high-throughput oncology

Kolmar, L., Autour, A., Ma, X., Vergier, B., Eduati, F., & Merten, C. A. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.04.008 · Cited by 16 · see citing works

Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions

Pal, K., & Sheth, R. A. (2022) · Cancers · doi:10.3390/cancers15010196 · Cited by 16 · see citing works

Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics

Tognon, C. E., Sears, R. C., Mills, G. B., Gray, J. W., & Tyner, J. W. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-043020-125955 · Cited by 15 · see citing works

A Miniaturized Platform for Multiplexed Drug Response Imaging in Live Tumors

Bhagavatula, S. K., Thompson, D., Ahn, S. W., Upadhyaya, K., Lammers, A., Deans, K., Dominas, C. A., Ferland, B., Valvo, V., Liu, G., et al. (2021) · Cancers · doi:10.3390/cancers13040653 · Cited by 14 · see citing works

The evolution of personalized medicine: literature review

Dolgopolov, I. S., & Rykov, M. Y. (2022) · Research and Practical Medicine Journal · doi:10.17709/2410-1893-2022-9-3-9 · Cited by 13 · see citing works

Thread as a Low-Cost Material for Microfluidic Assays on Intact Tumor Slices

Rumaner, M., Horowitz, L. F., Ovadya, A., & Folch, A. (2019) · Micromachines · doi:10.3390/mi10070481 · Cited by 13 · see citing works

Abstract 228: A novel device to perform rapid high-throughput in vivo drug sensitivity testing and identify optimal drug therapy for personalized cancer treatment

Jonas, O. H. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-228

Abstract 4381: High-throughput in vivo systems biology using implantable microdevices

Jonas, O. H. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4381 · Cited by 1 · see citing works

A Novel Device for Direct Determination of Tumor Chemotherapeutic Sensitivity

Wang, M., & Serak, J. (2015) · Neurosurgery · doi:10.1227/01.neu.0000471839.05005.18

Personalized Devices Predict Cancer Drug Sensitivity In Vivo:

Balakrishnan, V. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv267

Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy.

Traina, T. A., Plitas, G., Reis-Filho, J. S., Morris, E. A., Hughes, M. C., Sung, J. S., Patil, S. N., Piscuoglio, S., Park, S., Greenberg, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps1101 · Cited by 1 · see citing works